Quality over quantity: powering neuroimaging samples in psychiatry
- PMID: 38902353
- PMCID: PMC11525971
- DOI: 10.1038/s41386-024-01893-4
Quality over quantity: powering neuroimaging samples in psychiatry
Erratum in
-
Correction: Neuropsychopharmacology Volume 50 Issue 1.Neuropsychopharmacology. 2025 May;50(6):1019-1020. doi: 10.1038/s41386-025-02087-2. Neuropsychopharmacology. 2025. PMID: 40108440 Free PMC article. No abstract available.
Abstract
Neuroimaging has been widely adopted in psychiatric research, with hopes that these non-invasive methods will provide important clues to the underpinnings and prediction of various mental health symptoms and outcomes. However, the translational impact of neuroimaging has not yet reached its promise, despite the plethora of computational methods, tools, and datasets at our disposal. Some have lamented that too many psychiatric neuroimaging studies have been underpowered with respect to sample size. In this review, we encourage this discourse to shift from a focus on sheer increases in sample size to more thoughtful choices surrounding experimental study designs. We propose considerations at multiple decision points throughout the study design, data modeling and analysis process that may help researchers working in psychiatric neuroimaging boost power for their research questions of interest without necessarily increasing sample size. We also provide suggestions for leveraging multiple datasets to inform each other and strengthen our confidence in the generalization of findings to both population-level and clinical samples. Through a greater emphasis on improving the quality of brain-based and clinical measures rather than merely quantity, meaningful and potentially translational clinical associations with neuroimaging measures can be achieved with more modest sample sizes in psychiatry.
© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Conflict of interest statement
AMD reports that he was a Founder of and holds equity in CorTechs Labs, Inc., and serves on its Scientific Advisory Board. He is a member of the Scientific Advisory Board of Human Longevity, Inc. He receives funding through research grants from GE Healthcare to UCSD. The terms of these arrangements have been reviewed by and approved by UCSD in accordance with its conflict of interest policies. AMD also reports that he has memberships with the following research consortia: Alzheimer’s Disease Genetics Consortium (ADGC); Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA); Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL); Psychiatric Genomics Consortium (PGC). All other authors have no conflicts of interest.
References
-
- Liu S, Abdellaoui A, Verweij KJH, van Wingen GA. Replicable brain-phenotype associations require large-scale neuroimaging data. Nat Hum Behav. 2023;7:1344–56. - PubMed
-
- Button KS, Ioannidis JPA, Mokrysz C, Nosek BA, Flint J, Robinson ESJ, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 2013;14:365–76. - PubMed
-
- Szucs D, Ioannidis JPA. Sample size evolution in neuroimaging research: an evaluation of highly-cited studies (1990–2012) and of latest practices (2017–2018) in high-impact journals. Neuroimage. 2020;221:117164. - PubMed
